Janus Henderson Group PLC Has $865.61 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Janus Henderson Group PLC trimmed its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,575,363 shares of the company's stock after selling 346,533 shares during the quarter. Janus Henderson Group PLC owned about 8.48% of Vaxcyte worth $865,605,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Wells Fargo & Company MN lifted its stake in shares of Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock worth $5,916,000 after buying an additional 25,257 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Vaxcyte by 23.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after buying an additional 4,962 shares during the last quarter. TimesSquare Capital Management LLC lifted its stake in shares of Vaxcyte by 53.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after buying an additional 144,516 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Vaxcyte by 70.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock worth $49,418,000 after buying an additional 246,049 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Bank of America lowered their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Guggenheim reissued a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Cantor Fitzgerald started coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Finally, Needham & Company LLC reissued a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $136.50.

Vaxcyte Trading Up 3.1%

NASDAQ PCVX traded up $0.95 on Friday, hitting $31.85. 1,514,462 shares of the company were exchanged, compared to its average volume of 1,334,987. The firm has a 50 day moving average of $43.32 and a two-hundred day moving average of $72.46. The company has a market cap of $4.11 billion, a P/E ratio of -6.92 and a beta of 1.27. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period last year, the business posted ($0.85) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total value of $670,800.00. Following the transaction, the chief financial officer now owns 109,491 shares of the company's stock, valued at approximately $9,180,820.35. This trade represents a 6.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.